Human Genome Sciences (Nasdaq: HGSI) is a commercially focused biopharmaceutical company with one potentially major product approved by FDA in March 2011 and a broad pipeline of novel drugs in late- and mid-stage development.
Therapeutic and Commercial Potential
BENLYSTA® (belimumab) is the first new approved drug for lupus in more than fifty years.
In May 2009, we submitted a Biologics License Application to FDA for raxibacumab for the treatment of inhalation anthrax. We received a Complete Response Letter from the FDA in November 2009 and are working closely with the FDA to obtain approval.
In the first half of 2009, we achieved our first product sales by delivering 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax. In July 2009, we secured a new purchase order for 45,000 additional doses to be delivered over a three-year period. Approximately 21,000 doses have been delivered to date under the new purchase order, and we expect to deliver approximately 15,000 additional doses to the Stockpile in 2011.